Refractory nodular lymphocyte predominant Hodgkin lymphoma transformed to T-cell/histiocyte-rich B-cell lymphoma in an adolescent: salvage therapy with allogeneic bone marrow transplantation

Journal of Pediatric Hematology/oncology
Lucile CouronnéJean Pierre Vannier

Abstract

According to biologic features, there is a substantial "gray zone" between nodular lymphocyte predominant Hodgkin lymphomas (NLPHLs) (Poppema lymphomas) and T-cell/histiocyte-rich B-cell lymphomas (T/HRBCLs). Transformation from an NLPHL to a T/HRBCL can occur and is associated with a worsening of the prognosis. Here is described a case of a 16-year-old boy who presented with an NLPHL with features of T/HRBCL. Clinical evolution was complicated by 2 relapses leading to autologous and then to allogeneic bone marrow transplantation.

References

Jan 2, 1997·Bone Marrow Transplantation·M de LimaR E Champlin
Mar 4, 2000·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·N L HarrisC D Bloomfield
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Jun 25, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T RüdigerH K Müller-Hermelink
Oct 2, 2003·Bone Marrow Transplantation·S SeropianD L Cooper
Jan 30, 2004·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Julie M VoseMary M Horowitz
Aug 22, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ivan AksentijevichIan W Flinn

❮ Previous
Next ❯

Citations

Mar 25, 2010·Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society·Xiayuan LiangMichael Wang
Jan 22, 2011·Advances in Hematology·Pier Paolo PiccalugaStefano A Pileri

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.